Purchase this article with an account.
A. Husain, G. Blumenschein, B. Esmaeli; Management and Treatment Outcomes for Metastatic Sebaceous Cell Carcinoma of the Eyelid. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5233.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the management and the treatment outcomes in four patients with metastatic sebaceous cell carcinoma of the eyelid.
Retrospective, interventional review of case series
Average age at onset of metastasis was 66 years-old; all four cases were in females. Metastasis to the lungs (n=3) and regional lymph nodes (n=3) were the most common sites, followed by liver (n=2) and bone (n=1). Time from diagnosis of eyelid sebaceous cell carcinoma to metastasis ranged from 0 months (in the patient who had a parotid metastasis diagnosed at the time of eyelid mass diagnosis) to 5 years (mean of 3 years). Treatment of regional nodal metastasis included completion neck dissection followed by radiotherapy in 2 patients. Radiotherapy to the spine was administered in another patient with bony metastasis. A patient with lung metastasis received chemotherapy with carboplatin and doxetaxel followed by subtotal lung resection. Systemic chemotherapy was recommended in 2 additional patients, but one died shortly before systemic chemotherapy could be started and the other patient did not initiate treatment due to poor performance status and other ongoing medical problems. Two patients died during the study period. One patient died 1 month after diagnosis of distant metastatic disease; the other died 2 years after diagnosis of metastasis. The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months, mean of 19.8 months).
Sebaceous cell carcinoma of the eyelid can result in systemic metastasis and death. Clinical metastasis can be discovered as late as 5 years after treatment of the initial carcinoma, warranting continued and frequent surveillance of patients with eyelid sebaceous cell carcinoma to identify metastasis at its earliest possible stage.
This PDF is available to Subscribers Only